Hikma Pharmaceuticals (HIK) Completes Repurchase of 213,205 Shares in Latest Buyback Phase, Surpassing £185m of $250m Programme

Hikma Pharmaceuticals (HIK) Completes Repurchase of 213,205 Shares in Latest Buyback Phase, Surpassing £185m of $250m Programme →

Hikma Pharmaceuticals PLC (LSE: HIK), the global generic and branded medicines company listed in London and Dubai, announced the repurchase of 213,205 ordinary shares between 17 and 18 August 2026 as part of its ongoing $250 million share b…